Medicxi is a venture capital firm that focuses on advancing innovative biopharmaceutical technologies. The company supports the development of novel therapeutics, particularly in the fields of immuno-oncology and neurology. Notable projects include the backing of Ottimo Pharma, which is working on a bi-functional antibody targeting PD1 and VEGFR2, aimed at enhancing cancer treatment efficacy. Additionally, Medicxi has invested in companies like Centessa, which is developing an Orexin Receptor 2 (OX2R) agonist for sleep-related disorders, and Levicept, which is exploring a Neurotrophin-3 inhibitor for osteoarthritis management.

The firm is also involved in financing and supporting clinical studies for various innovative therapies. For instance, Vicebio is advancing a bivalent vaccine for respiratory viruses, while Vaderis has reported positive outcomes from a clinical trial related to hereditary hemorrhagic telangiectasia (HHT). Medicxi's portfolio reflects a commitment to fostering groundbreaking research and development in the biopharmaceutical sector, with a focus on addressing unmet medical needs through cutting-edge science and technology.

United Kingdom

Medicxi is an international investment firm focused on the life sciences sector. It wasestablished in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.

Medicxi

Company Details